Assessment Skin Quality and Efficacy of Dermal Line After Four Bipolar Radiofrequency Microneedling Treatments

University of Texas Southwestern Medical Center13 enrolled

Overview

This study intends to evaluate the safety and effectiveness of the InMode Morpheus8 System to treat facial and neck skin and assess its effect on skin quality and dermal lines. This device has been FDA cleared for full body subdermal adipose tissue remodeling.

The primary objective of this study is to evaluate the safety and efficacy of a bipolar fractional radiofrequency treatment via use of the InMode Morpheus8 System to achieve skin texture and quality change and to treat facial fine lines and wrinkles of the lower face.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Aging

Interventions

InMode Morpheus8 SystemDEVICE

The InMode Morpheus8 System is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis and neoelastogenesis.

Eligibility

Sex: ALLMin age: 21 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Healthy male and female adults between ages 21-70 years of age. 2. Presence of facial dermal lines and skin changes of the lower face associated with age or environmental exposure. 3. Confirmed BMI ≤ 35. 4. Subjects who can read, understand, and sign the Informed Consent Form. 5. Subjects willing and able to comply with all study requirements. 6. Fitzpatrick skin type I-VI. 7. Minimum of 1 on the Lemperle Wrinkle Assessment Scale, Allergan Fine Line Scale and Allergan Skin Roughness Scale 8. Subject is willing not to undergo any type of aesthetic procedure that could confound the study device treatment effects until he/she completes the study. Exclusion Criteria: 1. Active localized or systemic infections, that may alter wound healing. 2. Immunocompromised subjects. 3. Subjects with coagulation disorder. 4. History of skin photosensitivity disorders, or use of photosensitizing drugs (e.g., tetracycline or sulfa drugs). 5. Pregnant and/or lactating (All female volunteers will be advised about using birth control during the period of study). 6. 5 on the Lemperle Wrinkle Assessment Scale or 4 on the Allergan Fine Line Scale and/or Allergan Skin Roughness Scales 7. Scarring in areas to be treated. 8. Tattoos in the treatment areas to be treated. 9. Significant open facial wounds or lesions. 10. Severe or cystic acne in treatment areas. 11. Current active smoker. 12. Use of Accutane (Isotretinoin) within the past 6 months. 13. Use of topical retinoids within 48 hours. 14. Use of prescription anticoagulants. 15. Pacemaker or internal defibrillator. 16. History of skin disorders resulting in abnormal wound healing (i.e. keloids, extreme dry and fragile skin). 17. Subjects on current oral corticosteroid therapy or within the past 6 months 18. Metal implants in the treatment area. 19. In the opinion of the investigator, subject is unwilling or unable to adhere to all study requirements, including application and follow-up visits. 20. Subjects with a history of radiation therapy to the treatment area. 21. Subject has a history of allergy to lidocaine or ester-based local anesthetics. 22. Subjects with significant cardiac history or rhythm disturbance who may be unable to tolerate lidocaine with epinephrine. 23. Subjects with any skin pathology or condition in the treatment area that could interfere with evaluation or with the use of typical ancillary medical treatments or care used before, during or after treatments (e.g. psoriasis, rosacea, eczema, seborrheic dermatitis, vitiligo, hyper or hypo-skin pigmentation conditions such as post inflammatory hyperpigmentation). 24. Subjects who are unwilling to shave excessive hair in the treatment area that might influence or impair evaluation in the opinion of the Investigator. 25. Subjects have undergone skin resurfacing or tightening treatments in the treatment area over the past year. 26. Subjects have undergone dermatological treatments such as fillers and neurotoxins for the past 6 months in the treatment area. 27. Subjects have undergone laser and light treatments in the treatment area over the past 3 months. 28. Subjects have undergone superficial peel or microdermabrasion within 4 weeks.

Locations (1)

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Outcomes

Primary Outcomes

Change of Fine Lines and Wrinkles

Lemperle Wrinkle Assessment Scale- wrinkling will be assessed according to scales definitions. 0- No wrinkles 1. Just perceptible wrinkles 2. Shallow wrinkles 3. Moderately thick wrinkles 4. Deep wrinkles, well defined edges 5. Very deep wrinkles, redundant folds Lower value would indicate improvement.

Time frame: Baseline, 3 Months and 6 Months

Change of Fine Lines

Allergan Scale for Fine Lines- fine lines of the midface/cheeks will be assessed according to the scales definition. 0- None 1. Minimal (1-2 superficial lines) 2. Moderate (3-5 superficial lines) 3. Severe (\<5 superficial lines; no crosshatching) 4. Diffuse (diffuse superficial lines; crosshatching) Lower value would indicate improvement

Time frame: Baseline, 3 Months and 6 Months

Change of Skin Roughness

Allergan Skin Roughness Scale Assessment- roughness will be assessed according to the scaled definitions based on skin coarseness, crosshatching and elastosis in midface area. 0- None (smooth visual skin texture) 1. Minimal (slightly course and uneven visual skin texture) 2. Moderate (Moderately coarse and uneven visual skin texture; early elastosis) 3. Severe (severe coarse visual skin texture, crosshatching lines; some elastosis) 4. Diffuse (extreme coarse visual skin texture, deep crosshatched creases; extreme elastosis) Lower value would indicate improvement

Time frame: Baseline, 3 Months and 6 Months

Global Aesthetic Improvement Scale (GAIS)

Scale will be used to assess aesthetic change 1. Very much improved 2. Much improved 3. Improved 4. No Change 5. Worse Lower value would indicate improvement

Time frame: 3 Months and 6 Months

Secondary Outcomes

Adverse Events

Adverse events will be monitored at each visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.